Seeking Novel Research Programmes to Induce Specific Tregs in vivo

This campaign has been commissioned by an international Japanese pharmaceutical company who combat diseases using a combination of ground-breaking technology and biology, with an extensive track record of academic collaboration. They are seeking novel research programs which can induce tissue/antigen-specific regulatory T cells in vivo for immune disorders.

Specific Points of Interest

- Biology that can induce tissue or antigen specific regulatory T cells in vivo. In addition to Treg cell number, it is preferable to have functional data of induced Tregs (e.g. immune-suppression assay)
- Validation in mouse in vivo data and/or human in vitro data is of highest priority
- Modality: Any platform is within scope, with particular interests in antibodies, nucleic acid, small molecules and proteins/peptides

Diseases of Interest

Immune disorders are within scope for this campaign (for example, Multiple Sclerosis, Type 1 Diabetes, transplantation, Rheumatoid Arthritis, Inflammatory Bowel Disease, Systemic Lupus Erythematosus).

Out of Scope

- Cell therapy (ex vivo engineering of cell) are not within scope for this campaign
- Symptomatic treatments and treatments affecting entire immune response are not of interest

Developmental Stage

Our client is open to research from basic through to phase 1 clinical trials, however, submissions must contain a target as a minimum.

Incentives for Academics

Submissions will be reviewed on a case by case basis, with potential outcomes including the identification of opportunities for research collaboration or licensing on potential therapeutics.

Submission Information

Submission of 200-300 word research summary briefs are encouraged, along with any other non-confidential supporting documents. For example, this could include published papers, weblinks to academic profiles etc.

Opportunities sought

- Technologies
- Academics and expertise
- Centres of excellence
- Research projects
- Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online via: discover.in-part.com

Deadline: 15th March 2021 - 11:59 pm GMT

Have any questions?
Contact our team at discover@in-part.co.uk